Gunter von Minckwitz, MD, PhD | Authors

Articles

The Optimal Duration of Pertuzumab Treatment for Patients With HER2+ Breast Cancer

September 19, 2017

Gunter von Minckwitz, MD, PhD, president of the German Breast Group in Neu-Isenburg, Germany, discusses questions still surrounding the optimal duration of pertuzumab (Perjeta) treatment for patients with HER2-positive breast cancer.

Results of the Phase III APHINITY Trial in HER2-Positive Breast Cancer

July 05, 2017

Gunter von Minckwitz, MD, PhD, president of the German Breast Group in Neu-Isenburg, Germany, discusses results from the large phase III APHINITY trial, which explored the addition of pertuzumab (Perjeta) to adjuvant trastuzumab and chemotherapy for patients with HER2-positive early breast cancer.

The Mechanism of Action of Palbociclib

February 07, 2014

Gunter von Minckwitz, MD, PhD, Chairman, German Breast Group, Professor of Gynecology, University of Frankfurt, Germany, explains the mechanism of palbociclib, a novel oral selective inhibitor of cyclin-dependent kinase (CDK) 4 and 6